Highly active antiretroviral therapy (HAART) retreatment in patients on CD4-guided therapy achieved similar virologic suppression compared with patients on continuous HAART the HIV Netherlands Australia Thailand research collaboration 001.4 study

Journal of Acquired Immune Deficiency Syndromes

Volumn 39, Issue 5, 2005, Pages 523-529

  Ananworanich, Jintanat ^a   Siangphoe, Umaporn ^a   Hill, Andrew ^b   Cardiello, Peter ^a   Apateerapong, Wichitra ^a   Hirschel, Bernard ^c   Mahanontharit, Apicha ^a   Ubolyam, Sasiwimol ^a   Cooper, David ^d   Phanuphak, Praphan ^a,e   Ruxrungtham, Kiat ^a,e  

^a THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

CD4 guided; HAART; HIV; Intermittent therapy; Structured treatment interruption

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; LAMIVUDINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; VIRUS RNA; ZALCITABINE;

ADULT; ALGORITHM; ARTICLE; CLINICAL TRIAL; COST CONTROL; DISEASE COURSE; DRUG CAPSULE; DRUG COST; DRUG INTERMITTENT THERAPY; EDEMA; FEMALE; GEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LACTIC ACIDOSIS; LEUKOCYTE COUNT; LIPODYSTROPHY; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MUSCLE WEAKNESS; OPEN STUDY; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT PLANNING; VIRUS INFECTION; VIRUS LOAD; WEIGHT REDUCTION;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; AUSTRALIA; CD4 LYMPHOCYTE COUNT; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; NETHERLANDS; PILOT PROJECTS; RNA, VIRAL; THAILAND;

EID: 23244437092     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Fellay J, Boubaker K, Ledergerber B, et al. Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet. 2001;358:1322-1327.
2. Creese A, Floyd K, Alban A, et al. Cost-effectiveness of HIV/AIDS interventions in Africa: a systematic review of the evidence. Lancet. 2002; 359:1635-1643.
3. Hellinger FJ, Fleishman JA. Estimating the national cost of treating people with HIV disease: patient, payer, and provider data. J Acquir Immune Defic Syndr. 2000;24:182-188.
4. Walmsley S, Loutfy M. Can structured treatment interruptions (STIs) be used as a strategy to decrease total drug requirements and toxicity in HIV infection? J Int Assoc Physicians AIDS Care. 2002;1:95-103.
5. Hogg R, Heath K, Bangsberg D, et al. Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow up. AIDS. 2002;16:1051-1058.
6. Lundgren J, Vella S, Paddam L, et al. Interruption/stopping antiretroviral therapy and the risk of clinical disease: results from the EuroSIDA Study [abstract 48]. Presented at: Eighth Conference on Retroviruses and Opportunistic Infections; 2002; Boston.
7. Taylor S, Allen S, Fidler S, et al. Stop study: after discontinuation of efavirenz, plasma concentrations may persist for 2 weeks or longer [abstract 131]. Presented at: 10th Conference on Retroviruses and Opportunistic Infections; 2002; San Francisco.
8. Palmisano L, Giulano M, Pirillo M, et al. Baseline predictors and virological outcome in subjects developing mutations during intermittent HAART [abstract 143]. Presented at: XIII International HIV Drug Resistance workshop; 2004, Canary Islands.
9. Also published in Antivir Ther. 2004;9(Suppl):S159.
10. Lawrence J, Mayers D, Hullsiek K, et al. Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. N Engl J Med. 2003;349:837-846.
11. Katlama C, Dominguez S, Gourlain K, et al. Benefit of treatment interruption in HIV-infected patients with multiple therapeutic failures: a randomized controlled trial (ANRS 097). AIDS. 2004;18:217-226.
12. Mussini C, Cozzi-Lepri A, Borghi V, et al. CD4-guided treatment interruptions: a new possible treatment strategy [abstract F11/1]. Presented at: Ninth European AIDS Conference; 2003; Warsaw.
13. Dybul M, Chun T, Yoder C, et al. Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: effects on virologic, immunologic, and toxicity parameters. Proc Natl Acad Sci USA. 2001;98:15161-15166.
14. Ananworanich J, Nuesch R, Le Braz M, et al. Failures of 1 week on, 1 week off antiretroviral therapies in a randomised trial. AIDS. 2003; 17(Suppl):F33-F37.
15. Fagard C, Oxenius A, Gunthard H, et al. A prospective trial of structured treatment interruptions in human immunodeficiency virus infection. Arch Intern Med. 2003;163:1220-1226.
16. Dybul M, Nies-Kraske E, Daucher M, et al. Long-cycle structured intermittent versus continuous highly active antiretroviral therapy for the treatment of chronic infection with human immunodeficiency virus: effects on drug toxicity and on immunologic and virologic parameters. J Infect Dis. 2003;188:388-396.
17. Kroon ED, Ungsedhapand C, Ruxrungtham K, et al. A randomized, double-blind trial of half versus standard dose of zidovudine plus zalcitabine in Thai HIV-1-infected patients (study HIV-NAT 001). HIV Netherlands Australia Thailand Research Collaboration. AIDS. 2000;14: 1349-1356.
18. Cardiello P, van Heeswijk R, Hassink E, et al. Simplifying protease inhibitor therapy with once-daily dosing of saquinavir soft-gelatin capsules/ritonavir (1600/100 mg): HIVNAT 001.3 study. J Acquir Immune Defic Syndr. 2002;29:464-470.
19. Cardiello P, Hassink E, Ananworanich J, et al. Prospective randomized trial of structured treatment interruption (STI) in patients with chronic HIV infection. Clin Infect Dis. 2005;40:594-600.
20. Tebas P, Henry K, Mondy K, et al. Effect of prolonged discontinuation of successful antiretroviral therapy on CD4+ T cell decline in human immunodeficiency virus-infected patients: implications for intermittent therapeutic strategies. J Infect Dis. 2002;186:851-854.
21. Tarwater P, Parish M, Gallant J. Prolonged treatment interruption after immunologic response to highly active antiretroviral therapy. Clin Infect Dis. 2003;37:1541-1548.
22. Kempf DJ, King MS, Bernstein B. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J Infect Dis. 2004;189:51-60.
23. Kaufmann G, Perrin L, Pantaleo G, et al. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years. Arch Intern Med. 2003;163:2187-2195.
24. Cohen C, Morris A, Bazner S, et al. The FOTO Study: a pilot study of short-cycle treatment interruption, taking antiretroviral medications for five days on, two days off (FOTO), for those with viral load suppression on either PI or EFV-based regimens [abstract TuPeB4575]. Presented at: XV International AIDS Conference; 2004; Bangkok.
25. Fischer M, Hafner R, Schneider C, et al. HIV RNA in plasma rebounds within days during structured treatment interruption. AIDS. 2003;17:195-199.
26. Pattanapanyasat K, Lerdawa S, Shain H, et al. Low-cost enumeration in HIV-infected patients in Thailand. Asian Pac J Allergy Immunol. 2003;21: 104-113.
27. Staszewski S, Stark T, Knecht G, et al. The Quad study: a pilot study to assess the efficacy and safety of Trizivir + RTV boosted saquinavir (TZV+SQV/r) compared to Combivir + RTV-boosted saquinavir (CBV-SQV/r) in ART naive patients with high viral load (VL) and low CD4 count. 24 week interim results [abstract F1/1]. Presented at: Ninth European AIDS Conference (EACS); 2003; Warsaw.